- Prescribing Advice for GPs - https://www.prescriber.org.uk -

NICE Guidance - February 2012

The National Institute of Health and Clinical Excellence (NICE) has published new guidance for the month of February 2012. This month there is one technology appraisal that impact upon primary care.

Exenatide prolonged release (Bydureon®) has been reviewed in a technology appraisal and is approved for use in combination with oral therapies when glycaemic control is inadequate (HbA1c > 7.5% or 59mmol/mol) and:

It is also advised the treatment is reviewed at 6 months and discontinued if:

Action: Clinicians should be aware of this new guidance and implement any necessary changes to practice.